Keros Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M | $265.9M | $7.0M |
| Accounts Receivable | $3.6M | $2.7M | $143.0K | $0 | $18.0M | $0 | — |
| Inventory | — | — | — | — | — | — | — |
| Total Current Assets | $315.4M | $588.9M | $347.3M | $285.8M | $251.4M | $267.7M | $8.9M |
| Property, Plant & Equipment | $4.3M | $4.2M | $4.1M | $2.0M | $1.3M | $724.0K | $708.0K |
| Goodwill | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — |
| Total Assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M | $269.4M | $11.0M |
| Liabilities | |||||||
| Accounts Payable | $2.0M | $4.6M | $5.5M | $3.3M | $3.6M | $2.1M | $2.1M |
| Total Current Liabilities | $20.4M | $27.5M | $24.4M | $16.5M | $11.8M | $7.2M | $4.5M |
| Long-Term Debt | — | — | — | — | — | — | — |
| Total Liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M | $7.7M | $10.5M |
| Stockholders' Equity | |||||||
| Retained Earnings | $-481.8M | $-568.8M | $-381.4M | $-228.4M | $-123.8M | $-65.0M | $-19.7M |
| Total Stockholders' Equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M | $261.7M | $-19.4M |